诺和诺德预计2026年销售额将下降 引发股价暴跌

Core Viewpoint - Novo Nordisk (NVO.N) shares fell over 13% after the company unexpectedly warned of a more severe decline in sales for 2026, primarily due to pricing pressures affecting its diabetes and weight loss drugs in the U.S. [1] Sales Forecast - The company anticipates a global sales decline of 5% to 13% in 2026 compared to 2025 levels, excluding currency fluctuations [1] - In contrast, the sales for 2025 are projected to grow by 10% [1] Pricing Pressure - The decline in U.S. sales is attributed to price reductions for drugs, including Ozempic and Wegovy, following an agreement with the Trump administration to lower drug prices [1] - The loss of patent exclusivity for these drugs in certain countries outside the U.S. may open the market to lower-priced generic competition [1] Market Position - This negative outlook represents a setback for a company that was previously a pioneer in the weight loss drug market [1]